21/10/2014 20:03:57 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
10/20/20148:00AMBWUS FDA Accepts for Review a Biologics License Application for Merck & Sanofi Pasteur’s Investigational Pediatric Hexavalent...
Phase III clinical study data presented at IDWeek in Philadelphia Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies’ investigational... More...>>
10/20/20148:00AMPRNUSAward-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals Merkerson Visits Atlanta, Georgia on October 20 With America's Diabetes Challenge: Get to Your Goals Program PR Newswire WHITEHOUSE STATION, N.J., Oct. 20, 2014 WHITEHOUSE STATION, N.J., Oct. 20, 2014... More...>>
10/15/20148:00AMBWMerck Announces Final Results of Tender Offers for Eight Series of Notes
Merck & Co., Inc. (“Merck”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the final results of the previously announced offers to purchase (collectively, the “Offers”) any and all of the outstanding notes listed in the table below (collectively, the “Notes”). On Oct. 6... More...>>
10/14/20146:20PMBWMerck Announces Pricing of Tender Offers for Eight Series of Notes
Merck & Co., Inc. (“Merck”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the pricing of the previously announced offers to purchase (collectively, the “Offers”) any and all of the outstanding notes listed below (collectively, the “Notes”). The Offers are being made upon... More...>>
10/08/201411:13AMBWMerck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-517...
Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure... More...>>
10/06/201412:28PMBWMerck Prices EUR 2.5 Billion Debt Offering
Merck & Co., Inc. (the “Company”) (NYSE:MRK), known as MSD outside of the United States and Canada, priced today EUR 2.5 billion public offering of three series of Euro-denominated senior unsecured notes (collectively, the “New Notes”). Based on Oct. 3, 2014, closing exchange rates the EUR 2.5 billion equates... More...>>
10/06/20143:24AMBWMerck Announces Proposed Public Debt Offering
Merck & Co., Inc. (the “Company”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of a public offering of three series of Euro denominated senior unsecured notes due 2021, 2026 and 2034 (collectively, the “New Notes”). The exact terms and timing of the offering... More...>>
10/06/20143:18AMBWMerck Announces Tender Offers for Eight Series of Notes
Merck & Co., Inc. (“Merck”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of offers to purchase (collectively, the “Offers”) any and all of the outstanding notes listed below (collectively, the “Notes”). The Offers are being made upon, and are subject to... More...>>
10/03/20149:00AMBWMerck Congratulates Ecuador as Second Country to Receive PAHO/WHO Verification of Elimination of River Blindness
Merck (NYSE:MRK), known as MSD outside the United States and Canada, applauds the government of Ecuador on being the second country in the world to receive World Health Organization (WHO) verification of the elimination of river blindness (onchocerciasis) using MECTIZAN® (ivermectin). Ecuador worked in partnership with... More...>>
10/02/201410:57AMDJNEUROPE MARKETS: European Stocks Flop As ECB's Draghi Talks Stimulus
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- Stocks across Europe dropped Thursday, mired in the red as European Central Bank President Mario Draghi's efforts to invigorate the struggling eurozone economy fell flat on Thursday. The ECB said it will hold its main lending rate at 0.05%, and the interest rate paid... More...>>
10/02/201410:10AMDJNEUROPE MARKETS: European Stocks Fall As ECB's Draghi Talks Stimulus
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- Stocks across Europe dropped Thursday, stuck in the red as European Central Bank President Mario Draghi talked about monetary policy as the bank faces pressure to ramp up stimulus efforts for the struggling eurozone. The ECB said it will hold its main lending rate at... More...>>
10/02/20148:45AMDJNEUROPE MARKETS: European Stocks Fall; ECB Watched For Stimulus Details
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- Stocks across Europe were lower Thursday, stuck in the red after the European Central Bank matched the markets expectations by leaving interest rates unchanged. Markets are awaiting details around further steps the central bank may take to spur the sluggish European economy... More...>>
10/02/20145:54AMDJNEUROPE MARKETS: European Stocks Fall; ECB Watched For Stimulus Details
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- Stocks across Europe dropped Thursday, with investors waiting to hear from the European Central Bank about what it plans to do next to tackle low inflation levels and stagnating growth in the eurozone. Stimulus questions: The European Central Bank will release its rate... More...>>
10/02/20145:53AMDJNEUROPE MARKETS: European Stocks Fall; ECB Stimulus Details On Tap
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- Stocks across Europe dropped Thursday, with investors waiting to hear from the European Central Bank about what it plans to do next to tackle low inflation levels and stagnating growth in the eurozone. Stimulus questions: The European Central Bank will release its rate... More...>>
10/02/20143:50AMDJNBayer Sells $7 Billion Bond
BERLIN-- Bayer AG said Thursday it has sold $7 billion worth of bonds to help finance its acquisition of Merck & Co. Inc.'s over-the-counter medicine business. In May the German drug and pesticide maker agreed to buy Merck's consumer business for $14.2 billion. It said the bond comprises six tranches with short- mid... More...>>
10/01/20146:10PMDJNEsperion Reports Favorable Cholesterol Drug Data
Esperion Therapeutics Inc. (ESPR) reported favorable trial data for a cholesterol-reduction drug, pushing shares up sharply after hours. The company said a Phase 2b study of ETC-1002, its lead drug candidate, met its primary endpoint and the drug "appears to be safe and well tolerated." The 12-week study compared ETC-1002... More...>>
10/01/20145:58PMDJNEsperion Reports Favorable Cholesterol Drug Data -- Update
By Josh Beckerman Esperion Therapeutics Inc. (ESPR) reported favorable trial data for a cholesterol-reduction drug, pushing shares up sharply after hours. The company said a Phase 2b study of ETC-1002, its lead drug candidate, met its primary endpoint and the drug "appears to be safe and well tolerated." The 12-week study... More...>>
10/01/20145:10PMDJNEsperion Reports Favorable Cholesterol Drug Data
By Josh Beckerman Esperion Therapeutics Inc. (ESPR) reported favorable trial data for a cholesterol-reduction drug, pushing shares up sharply after hours. The company said a Phase 2b study of its ETC-1002 drug met its primary endpoint and the drug "appears to be safe and well tolerated." The 12-week study compared ETC-1002... More...>>
10/01/201411:30AMBWMerck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion
Worldwide Collaboration to Market and Develop Portfolio of Soluble Guanylate Cyclase (sGC) Modulators Commences Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has completed the previously announced sale of the Merck Consumer Care (MCC) business to Bayer AG. Effective today, Bayer will... More...>>
09/29/20146:52PMBWMSD stellt erste Ergebnisse zum Prüfgebrauch von Pembrolizumab bei Patienten mit fortgeschrittenem Blasenkrebs auf der ESMO ...
Pembrolizumab-Monotherapie erzielt Gesamtansprechen von 24 Prozent bei Patienten mit PD-L1-positivem fortgeschrittenem Blasenkrebs (Urothelkarzinom) Geplante Phase-3-Studie zu fortgeschrittenem Blasenkrebs soll Ende 2014 eingeleitet werden MSD, in den USA und Kanada als Merck firmierend, meldete heute die erstmalige Präsentation... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk141021 20:03